NCT05940272 Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers Status RECRUITING Phase NA
NCT05929716 An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Status WITHDRAWN Phase PHASE2
NCT05887167 Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Status RECRUITING Phase PHASE1
NCT05826535 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT05820841 Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE3
NCT05794958 Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Status RECRUITING Phase PHASE1
NCT05776160 Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Status AVAILABLE Phase N/A
NCT05757700 Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05665062 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05648019 CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Status RECRUITING Phase PHASE2
NCT05643742 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Status RECRUITING Phase PHASE1/PHASE2
NCT05464719 A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Status RECRUITING Phase PHASE2
NCT05464329 Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05429268 Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05377307 Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy Status RECRUITING Phase N/A
NCT05326243 Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT05108805 Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Status COMPLETED Phase PHASE4